Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The establishment of the Intel Universal Quick Disconnect (UQD) Alliance, with the company as one of the first certified partners, is expected to enhance the liquid cooling ecosystem and reduce total cost of ownership (TCO) for customers [5] - The company is projected to benefit from the ongoing growth in data center construction driven by the demand for high-power computing chips and cabinets, with net profits expected to reach 651 million, 1.097 billion, and 1.519 billion yuan for 2025, 2026, and 2027 respectively [5] - The company has significantly increased its research and development (R&D) investment, with R&D expenses reaching 196 million yuan in the first half of 2025, a year-on-year increase of 36.74% [7] Financial Summary - The company's total revenue is projected to grow from 3.529 billion yuan in 2023 to 12.823 billion yuan in 2027, reflecting a compound annual growth rate (CAGR) of 35.1% [8] - The net profit attributable to the parent company is expected to increase from 344 million yuan in 2023 to 1.519 billion yuan in 2027, with a year-on-year growth rate of 38.6% in 2027 [8] - The company's gross margin is forecasted to stabilize around 30% in the coming years, with a net margin projected to reach 11.8% by 2027 [11]

计算机/软件开发 Q2 收入增速明显回暖，WPS AI 月活高速增长 2025 年 08 月 21 日 投资评级：买入（维持） | 日期 | 2025/8/20 | | --- | --- | | 当前股价(元) | 300.99 | | 一年最高最低(元) | 408.68/167.18 | | 总市值(亿元) | 1,394.12 | | 流通市值(亿元) | 1,394.12 | | 总股本(亿股) | 4.63 | | 流通股本(亿股) | 4.63 | | 近 3 个月换手率(%) | 56.87 | 股价走势图 数据来源：聚源 -40% 0% 40% 80% 120% 2024-08 2024-12 2025-04 金山办公 沪深300 相关研究报告 《WPS AI 月活近 2000 万，WPS 365 开启新增长引擎—公司信息更新报 告》-2025.3.20 《业绩超预期，携手 Deepseek 开启认 知智能新范式—公司信息更新报告》 -2025.3.2 《业绩符合预期，Q3 现金流高速增长 —公司信息更新报告》-2024.10.27 | 陈宝健（分析师） | 刘逍遥（分析师） | | --- ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][18] Core Views - The company has received FDA Breakthrough Therapy Designation (BTD) for its EGFR/HER3 bispecific antibody-drug conjugate Iza-bren (BL-B01D1), aimed at treating advanced or metastatic non-small cell lung cancer (NSCLC) after previous treatments have failed [6][7] - The company is expected to maintain its revenue forecasts, with projected revenues of 2.205 billion, 2.290 billion, and 960 million yuan for the years 2025, 2026, and 2027 respectively [6][10] - The current price-to-sales (P/S) ratios are projected to be 42.2, 40.7, and 97.1 for the years 2025, 2026, and 2027 respectively, indicating a strong market position [6][10] Financial Summary - The total market capitalization of the company is 125.04 billion yuan, with a circulating market capitalization of 32.084 billion yuan [1] - The company reported a revenue of 562 million yuan in 2023, with a year-over-year change of -20.1%, and is expected to see a significant increase in 2024 to 5.823 billion yuan [10][14] - The gross margin is projected to be 87.0% in 2025, with a net profit margin of -41.0% [10][14] - The company is expected to incur a net loss of 905 million yuan in 2025, with a significant increase in losses projected for 2027 at 2.691 billion yuan [10][14]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's Q2 2025 performance shows significant improvement, with a quarter-on-quarter revenue increase of 14.12% and a net profit increase of 25.40% [4] - The company is expected to continue achieving its stock incentive goals, driven by new product launches and accelerated overseas revenue growth [4] - The projected net profits for 2025-2027 are 271 million, 319 million, and 379 million yuan respectively, with corresponding EPS of 1.53, 1.80, and 2.15 yuan [4] Financial Summary - For H1 2025, the company reported revenue of 654 million yuan (down 2.25% year-on-year) and a net profit of 137 million yuan (down 6.77% year-on-year) [4] - Q2 2025 revenue was 349 million yuan (down 1.61% year-on-year, up 14.12% quarter-on-quarter) and net profit was 76 million yuan (up 6.29% year-on-year, up 25.40% quarter-on-quarter) [4] - The company’s revenue is projected to grow from 1,532 million yuan in 2025 to 2,109 million yuan in 2027, with a year-on-year growth rate of 13.5% and 18.5% respectively [8] Business Development - The company has recently received approvals for new products, including sodium nalbuphine injection and butorphanol tartrate injection, contributing to revenue growth [5] - The company is actively expanding its international market presence, with regular shipments of nicardipine hydrochloride injection and plans for a naloxone nasal spray submission in September 2024 [5] - The company has increased its stake in Chao Yang to 30.68%, enhancing its innovation platform value [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's revenue for H1 2025 was 1.246 billion yuan, a year-over-year decrease of 20.92%, with a net profit attributable to shareholders of 189 million yuan, down 46.82% year-over-year. In Q2 2025, revenue was 445 million yuan, a decline of 37.64%, and net profit was 6,350 yuan, down 99.95% year-over-year [4][5] - The increase in expense ratios is attributed to a decline in revenue base, with sales expense ratio at 25.6% (+5.38 percentage points), management expense ratio at 7.34% (+0.52 percentage points), and R&D expense ratio at 13.99% (+1.46 percentage points). The gross margin was 62.87% (-1.47 percentage points) and net margin was 15.27% (-7.48 percentage points) due to industry policy adjustments affecting terminal testing volume and pricing [4][5] - The company has adjusted its profit forecasts for 2025-2027, expecting net profits of 428 million, 499 million, and 600 million yuan respectively, with corresponding EPS of 0.89, 1.04, and 1.25 yuan. The current stock price corresponds to P/E ratios of 26.1, 22.3, and 18.6 times for the respective years [4][5] Summary by Sections Financial Performance - In H1 2025, the infectious disease business generated 379 million yuan (down 21.14% year-over-year), primarily due to lower respiratory disease prevalence and medical load. Chronic disease management testing revenue was 563 million yuan (down 26.06% year-over-year) due to policy adjustments affecting terminal demand [5] - Drug testing revenue increased to 145 million yuan (up 4.26% year-over-year), supported by localized operations and channel expansion, with the U.S. Amazon platform ranking first in sales [5] - The company continues to enhance its product offerings and expand into international markets, with significant growth in overseas revenue, particularly in Europe, Asia, and Latin America [6] Market Strategy - The company is focusing on developing markets, establishing subsidiaries in Russia and the Philippines in H1 2025. The introduction of chemiluminescence products is aimed at penetrating the mid-to-high-end market, with rapid growth in overseas installations [6] - In the U.S. market, the company received FDA 510(k) approval for a COVID-19 and flu testing product in January 2025, which is expected to drive revenue growth through comprehensive sales channel coverage [6]

医药生物/化学制药 华东医药（000963.SZ） 创新药收入快速增长，多产品步入收获期 2025 年 08 月 21 日 相关研究报告 《创新转型再出发，多产品步入收获 期—公司深度报告》-2025.6.2 | 余汝意（分析师） | 余克清（分析师） | 刘艺（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | yukeqing@kysec.cn | liuyi1@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790525010002 | 证书编号：S0790124070022 | 创新药收入快速增长，多产品步入收获期，维持"买入"评级 2025H1 公司收入 216.75 亿元（同比+3.39%，以下为同比口径）；归母净利润 18.15 亿元（+7.00%）；扣非归母净利润 17.62 亿元（+8.40%）。2025H1 公司毛利率 33.9% （+1.2pct）；净利率 8.32%（+0.27pct）。2025H1 销售费用率 14.90%（-0.72pct）； 管理费用率 3.35%（-0.06pct）；研发费用率 4.6 ...

Investment Rating - The investment rating for Xiaomi Group-W (01810.HK) is "Buy" (maintained) [1] Core Views - The brand momentum remains strong, awaiting the release of automotive production capacity and the initiation of a new vehicle cycle [1] - The forecast for net profit attributable to shareholders for 2025-2027 has been adjusted downwards to 415 billion, 555 billion, and 686 billion CNY, respectively, reflecting a year-on-year growth of 52%, 34%, and 24% [1][4] - The current stock price of 52.55 HKD corresponds to a PE ratio of 30.1, 22.6, and 18.2 for the years 2025-2027 [1] Financial Summary and Valuation Metrics - Revenue for 2023A is 270,970 million CNY, with a year-on-year change of -3.2% [8] - Net profit for 2023A is 19,273 million CNY, with a year-on-year change of 126.3% [8] - Gross margin for 2023A is 21.2%, and net margin is 7.1% [8] - The diluted EPS for 2025E is projected at 1.59 CNY, with a PE ratio of 30.1 [8] - The company aims to achieve profitability in its automotive and new business segments in the second half of 2025 [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][4][11] Core Views - The report highlights a positive outlook on the mobile optical upgrade cycle and the acceleration of automotive optical applications, maintaining a "Buy" rating. The forecast for net profit from 2025 to 2027 has been revised upwards due to improvements in ASP and gross margin in the mobile business [4][6] - The company is expected to benefit from the release of flagship models in the second half of 2025, with mobile revenue projected to grow by 5%-10% year-on-year [5][6] Financial Summary - The company's total revenue is projected to increase from 31.681 billion in 2023 to 41.823 billion in 2025, representing a year-on-year growth of 9.2% [7] - The net profit attributable to the parent company is expected to rise from 1.099 billion in 2023 to 3.810 billion in 2025, with a year-on-year growth of 41.1% [7] - The gross margin is forecasted to improve from 14.5% in 2023 to 20.5% in 2025, indicating a positive trend in profitability [7] Business Segments - Mobile business revenue for the first half of 2025 was 132 billion, showing a year-on-year growth of 2%, primarily driven by ASP increases in modules and lenses [5] - Automotive ADAS revenue for the first half of 2025 reached 34 billion, up 18% year-on-year, with expectations for over 20% growth in 2025 [6] - XR revenue for the first half of 2025 was 12 billion, reflecting a 21% increase, mainly from smart glass projects [6]

Group 1: Macro Economic Insights - The report highlights that after the implementation of the "Equal Tariff 2.0," industry tariffs may become a key new variable in Trump's tariff policy, aiming to reduce the trade deficit and promote manufacturing job recovery in the U.S. [5][8][9] - The U.S. has reached trade agreements with several countries, but most are temporary framework agreements lacking specific content, with significant tariff rate disparities remaining [5][6][7]. - The report notes that the U.S. collected approximately $94.719 billion in tariffs from April to July 2025, indicating a partial achievement of the goal to supplement U.S. fiscal revenue through tariffs [8]. Group 2: Industry Performance - The report indicates that in July 2025, the sales of new energy vehicles in nine European countries reached 217,000 units, a year-on-year increase of 41.6%, with a penetration rate of 27.5% [32]. - The report suggests that the European electric vehicle market is expected to grow further due to new carbon emission regulations and the introduction of new electric vehicle models by various manufacturers [34]. - The agricultural sector, particularly companies like BioShares, is experiencing growth driven by accelerated vaccine development and a strong product pipeline, with revenue for the first half of 2025 reaching 620 million yuan, a year-on-year increase of 1.28% [36][39]. Group 3: Company-Specific Updates - The report states that TaxFriend Co. is expected to benefit from the deepening of fiscal and tax reforms, with projected net profits for 2025-2027 at 212 million, 332 million, and 498 million yuan respectively [46]. - JiBit Co. reported a significant revenue increase of 28.49% year-on-year for the first half of 2025, driven by the success of new game launches and a high dividend payout ratio of 73% [51][52]. - JiaBiyou Co. anticipates continued growth in the second half of 2025, with a projected net profit of 192 million yuan for 2025, supported by favorable market conditions and ongoing restructuring efforts [55][56].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is accelerating the research and development of non-epidemic vaccines, with strong growth momentum from multiple new products [3][5] - Despite short-term pressure on performance, the company maintains its profit forecasts for 2025-2027, expecting net profits of 188 million, 352 million, and 508 million yuan respectively [3][4] - The current stock price corresponds to a price-to-earnings ratio (PE) of 54.2, 29.0, and 20.1 for the years 2025, 2026, and 2027 respectively [3][4] Financial Performance - In the first half of 2025, the company's revenue was 620 million yuan (up 1.28% year-on-year), and the net profit attributable to the parent company was 60 million yuan (down 50.84% year-on-year) [3][4] - The second quarter of 2025 saw revenue of 268 million yuan (up 1.58% year-on-year), with a net profit of -16 million yuan [3][4] - The company’s R&D expenses in the first half of 2025 were 73 million yuan, an increase of 25.62% year-on-year [5] Product Development - The company is focusing on optimizing its product structure, with significant growth in core products such as non-foot-and-mouth disease vaccines, which saw revenue growth exceeding 20% [4] - The company has established a dedicated technical service team for poultry vaccines, leading to a nearly 40% year-on-year increase in revenue from key poultry vaccine products [4] - The company is also expanding its overseas market presence, with sales of pig foot-and-mouth disease vaccines in Vietnam doubling year-on-year [4]